Switch theme
Sign up to access all valuation multiples
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
2016
323
LTM Revenue $292M
LTM EBITDA -$74.5M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Tarsus Pharmaceuticals has a last 12-month revenue (LTM) of $292M and a last 12-month EBITDA of -$74.5M.
In the most recent fiscal year, Tarsus Pharmaceuticals achieved revenue of $183M and an EBITDA of -$107M.
Tarsus Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Tarsus Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $292M | XXX | $183M | XXX | XXX | XXX |
| Gross Profit | $271M | XXX | $170M | XXX | XXX | XXX |
| Gross Margin | 93% | XXX | 93% | XXX | XXX | XXX |
| EBITDA | -$74.5M | XXX | -$107M | XXX | XXX | XXX |
| EBITDA Margin | -26% | XXX | -58% | XXX | XXX | XXX |
| EBIT | -$86.8M | XXX | -$121M | XXX | XXX | XXX |
| EBIT Margin | -30% | XXX | -66% | XXX | XXX | XXX |
| Net Profit | -$81.8M | XXX | -$116M | XXX | XXX | XXX |
| Net Margin | -28% | XXX | -63% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Tarsus Pharmaceuticals's stock price is $40.
Tarsus Pharmaceuticals has current market cap of $1.7B, and EV of $1.3B.
See Tarsus Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.7B | XXX | XXX | XXX | XXX | $-2.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Tarsus Pharmaceuticals has market cap of $1.7B and EV of $1.3B.
Tarsus Pharmaceuticals's trades at 7.3x EV/Revenue multiple, and -12.6x EV/EBITDA.
Equity research analysts estimate Tarsus Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tarsus Pharmaceuticals has a P/E ratio of -20.5x.
See valuation multiples for Tarsus Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.7B | XXX | $1.7B | XXX | XXX | XXX |
| EV (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV/Revenue | 4.6x | XXX | 7.3x | XXX | XXX | XXX |
| EV/EBITDA | -18.0x | XXX | -12.6x | XXX | XXX | XXX |
| EV/EBIT | -15.5x | XXX | -11.2x | XXX | XXX | XXX |
| EV/Gross Profit | 5.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -20.5x | XXX | -14.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -15.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTarsus Pharmaceuticals's last 12 month revenue growth is 67%
Tarsus Pharmaceuticals's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.9M for the same period.
Tarsus Pharmaceuticals's rule of 40 is -688% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Tarsus Pharmaceuticals's rule of X is 143% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Tarsus Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 67% | XXX | 77% | XXX | XXX | XXX |
| EBITDA Margin | -26% | XXX | -58% | XXX | XXX | XXX |
| EBITDA Growth | -162% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -688% | XXX | 9% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 143% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 29% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 159% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tarsus Pharmaceuticals acquired XXX companies to date.
Last acquisition by Tarsus Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Tarsus Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Tarsus Pharmaceuticals founded? | Tarsus Pharmaceuticals was founded in 2016. |
| Where is Tarsus Pharmaceuticals headquartered? | Tarsus Pharmaceuticals is headquartered in United States of America. |
| How many employees does Tarsus Pharmaceuticals have? | As of today, Tarsus Pharmaceuticals has 323 employees. |
| Who is the CEO of Tarsus Pharmaceuticals? | Tarsus Pharmaceuticals's CEO is Dr. Bobak Azamian, M.D.,PhD. |
| Is Tarsus Pharmaceuticals publicy listed? | Yes, Tarsus Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Tarsus Pharmaceuticals? | Tarsus Pharmaceuticals trades under TARS ticker. |
| When did Tarsus Pharmaceuticals go public? | Tarsus Pharmaceuticals went public in 2020. |
| Who are competitors of Tarsus Pharmaceuticals? | Similar companies to Tarsus Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Tarsus Pharmaceuticals? | Tarsus Pharmaceuticals's current market cap is $1.7B |
| What is the current revenue of Tarsus Pharmaceuticals? | Tarsus Pharmaceuticals's last 12 months revenue is $292M. |
| What is the current revenue growth of Tarsus Pharmaceuticals? | Tarsus Pharmaceuticals revenue growth (NTM/LTM) is 67%. |
| What is the current EV/Revenue multiple of Tarsus Pharmaceuticals? | Current revenue multiple of Tarsus Pharmaceuticals is 4.6x. |
| Is Tarsus Pharmaceuticals profitable? | Yes, Tarsus Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Tarsus Pharmaceuticals? | Tarsus Pharmaceuticals's last 12 months EBITDA is -$74.5M. |
| What is Tarsus Pharmaceuticals's EBITDA margin? | Tarsus Pharmaceuticals's last 12 months EBITDA margin is -26%. |
| What is the current EV/EBITDA multiple of Tarsus Pharmaceuticals? | Current EBITDA multiple of Tarsus Pharmaceuticals is -18.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
